ATBPF:OTC-Antibe Therapeutics Inc (USD)

COMMON STOCK | Medical Devices | OTC

Last Closing Price

USD 0.61

Change

+0.00 (+0.07)%

Market Cap

USD 0.03B

Avg Analyst Target

USD 4.00 (+561.16%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


Antibe Therapeutics Inc (ATBPF) Stock Analysis:
Based on the Antibe Therapeutics Inc stock forecasts from 1 analysts, the average analyst target price for Antibe Therapeutics Inc is USD 4.00 over the next 12 months. Antibe Therapeutics Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Antibe Therapeutics Inc is Neutral, which is based on 4 positive signals and 4 negative signals. At the last closing, Antibe Therapeutics Inc’s stock price was USD 0.61. Antibe Therapeutics Inc’s stock price has changed by +0.05% over the past week, +0.06% over the past month and -81.21% over the last year.

About

Antibe Therapeutics Inc., a biotechnology company, originates, develops, and out-licenses patent novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. Its drugs are designed t ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-01-19 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
SEMHF Siemens Healthineers AG

N/A

USD79.26B 39.40 24.15
SMMNY Siemens Healthineers AG

+0.48 (+1.45%)

USD76.99B 37.98 24.15
RYLPF Koninklijke Philips N.V

+0.36 (+1.06%)

USD30.29B 7.25 30.12
SONVF Sonova Holding AG

+0.02 (+0.01%)

USD21.98B 30.13 22.13
SONVY Sonova Holding AG

+1.21 (+1.73%)

USD21.85B 30.20 22.13
SNNUF Smith & Nephew plc

N/A

USD15.66B 28.25 13.97
WILLF Demant A/S

N/A

USD11.92B 35.40 4.34
GNGBF Getinge AB

+0.37 (+1.03%)

USD11.74B 16.60 1.74
WILYY Demant A/S

N/A

USD11.38B 33.62 4.34
GNGBY Getinge AB

+0.15 (+0.41%)

USD10.14B 16.02 1.74

ETFs Containing ATBPF

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Medical Devices)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 17.27% 79% C+ 85% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 17.27% 79% C+ 85% B
Trailing 12 Months  
Capital Gain -81.21% 12% F 10% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -81.21% 12% F 10% F
Trailing 5 Years  
Capital Gain -56.16% 41% F 26% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -56.16% 41% F 25% F
Average Annual (5 Year Horizon)  
Capital Gain 44.86% 67% D+ 70% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 44.86% 67% D+ 69% D+
Risk Return Profile  
Volatility (Standard Deviation) 92.32% 46% F 35% F
Risk Adjusted Return 48.60% 69% D+ 72% C-
Market Capitalization 0.03B 49% F 41% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Medical Devices)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 0.50 92% A- 83% B
Price / Cash Flow Ratio -274.31 98% A+ 97% A+
EV/EBITDA 0.96 88% B+ 66% D
Management Effectiveness  
Return on Equity -62.19% 29% F 15% F
Return on Invested Capital -86.25% 17% F 9% F
Return on Assets -26.93% 46% F 21% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta -0.18 77% C+ 86% B
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Underpriced on free cash flow basis

The stock is trading low compared to its peers on a price to free cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector